MDxHealth Interim Report Reveals $10.4M Medicare Recoupment Claim, Delta Lab Wind-Down, and Going Concern Uncertainty
MDXH sits 81% above its 52-week low of $0.4.
Summary
MDxHealth's interim report discloses a $10.4M Medicare recoupment claim, the wind-down of its Delta Lab subsidiary via an Assignment for the Benefit of Creditors, and going concern uncertainty, alongside the previously reported $20M raise.
Key Events · Earnings and Guidance · MDXH
-
Delta Lab ABC and Deconsolidation
Delta Lab executed an Assignment for the Benefit of Creditors on August 3, 2026, assigning substantially all assets to an assignee. Control passed to the assignee, and Delta Lab will be deconsolidated in Q3 2026, with a non-cash gain expected within discontinued operations.
-
$10.4M Medicare Recoupment Claim
Delta Lab received a Medicare contractor recoupment decision dated April 13, 2026, totaling approximately $10.4 million related to historical Resolve mdx claims. The Company is contesting the decision and has not recorded an accrual, treating it as a contingent liability.
-
Going Concern Uncertainty
The interim financial statements include going concern language stating that material uncertainty exists casting substantial doubt about the Company's ability to continue as a going concern, despite $19.2 million in cash as of June 30, 2026, and the $20 million August raise.
-
Resolve UTI Business Discontinued
The Board approved discontinuation of the Resolve UTI testing offering and closure of the Plano, Texas laboratory, completed by June 30, 2026. The business is presented as discontinued operations with a $1.2 million loss for the six months.
Analysis · MDXH · Industrial Applications And Services
This interim report contains several first-time disclosures that materially change the risk profile. The $10.4 million Medicare recoupment claim against Delta Lab is being contested but represents a significant contingent liability. The Assignment for the Benefit of Creditors executed on August 3, 2026, means Delta Lab is being deconsolidated, effectively walking away from that subsidiary and its liabilities. The going concern language confirms material uncertainty about the company's ability to continue operations, despite the $20 million raise in August. The Resolve UTI business discontinuation and the GPS earnout amendment with Exact Sciences (deferring $39.5 million in payments to 2027-2028 in exchange for 3 million warrants) further reshape the capital structure and cash obligations.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 36.1% of the 1753 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.04%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MDXH was trading at $0.72 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $68.9M. The 52-week trading range was $0.40 to $5.33. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.